MedPath

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

Phase 4
Completed
Conditions
Secondary Amenorrhea
Interventions
Registration Number
NCT00160199
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
240
Inclusion Criteria
  • Women with secondary amenorrhea
  • Normal serum Dehydroepiandrosterone (DHEA), prolactin, testosterone, Thyroid Stimulating Hormone (TSH) and thyroxine
Exclusion Criteria
  • Primary amenorrhea
  • Other medical conditions resulting in amenorrhea (e.g. Asherman's syndrome)
  • Peanut allergy
  • Allergy to progestational steroids

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2PROMETRIUM® 400 mg-
1PROMETRIUM® 300 mg-
Primary Outcome Measures
NameTimeMethod
Secretory Conversion of the EndometriumEnd of the study (Days 85)

Endometrial biopsy results were classified as : Secretory (Complete or partial), Non-secretory, Unable to determine or Unknown after an evaluation of morphologic criteria.

Number of Subjects With Withdrawal BleedingAfter first and second cycle (cycle=28 days)

This measure is the number of subjects with withdrawal bleeding using Last Observation Carried Forward (LOCF) after first and second cycle.

Secondary Outcome Measures
NameTimeMethod
The Duration of Withdrawal Bleeding After Second Treatment CycleEnd of the second cycle of treatment (cycle=28 days)

The numbers of days the subjects actually bled after the end of the second treatment cycle

Maximum Intensity of Withdrawal Bleeding After Any CycleDuration of withdrawal bleed

The intensity of withdrawal bleeding was classified by: None, Spotting, Light, Moderate, Heavy

The Duration of Withdrawal Bleeding After the First Treatment CycleEnd of the first cycle of treatment (cycle=28 days)

The numbers of days the subjects actually bled after the end of the first treatment cycle.

Time to Withdrawal Bleeding After First Treatment CycleEnd of the first cycle of treatment (cycle=28 days)

The number of days between the first cycle of treatment and the withdrawal bleeding.

Time to Withdrawal Bleeding After Second Treatment CycleEnd of the second cycle of treatment (cycle=28 days)

The number of days between the second cycle of treatment and the withdrawal bleeding

Trial Locations

Locations (42)

Site 7

🇺🇸

Baltimore, Maryland, United States

Site 16

🇺🇸

Reno, Nevada, United States

Site 14

🇺🇸

Aventura, Florida, United States

Site 6

🇺🇸

Baton Rouge, Louisiana, United States

Site 15

🇺🇸

Winston-Salem, North Carolina, United States

Site 41

🇺🇸

Montgomery, Alabama, United States

Site 36

🇺🇸

Champaign, Illinois, United States

Site 3

🇺🇸

Groton, Connecticut, United States

Site 37

🇺🇸

West Hartford, Connecticut, United States

Site 29

🇺🇸

Mobile, Alabama, United States

Site 39

🇺🇸

Carmichael, California, United States

Site 46

🇺🇸

Atlanta, Georgia, United States

Site 42

🇺🇸

Avon, Connecticut, United States

Site 40

🇺🇸

Clearwater, Florida, United States

Site 9

🇺🇸

Waterbury, Connecticut, United States

Site 23

🇺🇸

New Bern, North Carolina, United States

Site 5

🇺🇸

Jonesboro, Arkansas, United States

Site 30

🇺🇸

West Palm Beach, Florida, United States

Site 26

🇺🇸

Tucson, Arizona, United States

Site 43

🇺🇸

Powder Springs, Georgia, United States

Site 45

🇺🇸

New York, New York, United States

Site 19

🇺🇸

Norfolk, Virginia, United States

Site 12

🇺🇸

Chicago, Illinois, United States

Site 27

🇺🇸

Houston, Texas, United States

Site 4

🇺🇸

Seattle, Washington, United States

Site 10

🇺🇸

San Diego, California, United States

Site 33

🇺🇸

Cincinnati, Ohio, United States

Site 24

🇺🇸

San Antonio, Texas, United States

Site 35

🇺🇸

Salt Lake City, Utah, United States

Site 17

🇺🇸

Encinitas, California, United States

Site 22

🇺🇸

New Britian, Connecticut, United States

Site 1

🇺🇸

West Palm Beach, Florida, United States

Site 2

🇺🇸

St. Louis, Missouri, United States

Site 47

🇺🇸

Hershey, Pennsylvania, United States

Site 28

🇺🇸

Winston-Salem, North Carolina, United States

Site 13

🇺🇸

Greenville, South Carolina, United States

Site 34

🇺🇸

Houston, Texas, United States

Site 8

🇺🇸

Conroe, Texas, United States

Site 32

🇺🇸

Erie, Pennsylvania, United States

Site 11

🇺🇸

Corpus Christi, Texas, United States

Site 38

🇺🇸

Pottstown, Pennsylvania, United States

Site 44

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath